Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q13258
UPID:
PD2R_HUMAN
Alternative names:
Prostanoid DP receptor
Alternative UPACC:
Q13258; G3V5L3; Q13250; Q13251; Q1ZZ52
Background:
The Prostaglandin D2 receptor, also known as the Prostanoid DP receptor, plays a pivotal role in mediating the effects of prostaglandin D2 (PGD2). This receptor's activation primarily triggers G(s) proteins, enhancing adenylate cyclase activity and raising intracellular cAMP levels. Additionally, it facilitates calcium mobilization, contributing to various physiological responses.
Therapeutic significance:
Given its involvement in asthma-related traits, including symptoms like coughing, wheezing, and dyspnea, the Prostaglandin D2 receptor is a key target in asthma research. Understanding its function could lead to novel therapeutic strategies for managing asthma and related conditions.